- Home
- APPN vs VRNA Comparison
APPN vs VRNA Comparison
Compare APPN & VRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APPN
- VRNA
- Stock Information
- Founded
- APPN 1999
- VRNA 2005
- Country
- APPN United States
- VRNA United Kingdom
- Employees
- APPN N/A
- VRNA N/A
- Industry
- APPN Computer Software: Prepackaged Software
- VRNA Biotechnology: Pharmaceutical Preparations
- Sector
- APPN Technology
- VRNA Health Care
- Exchange
- APPN Nasdaq
- VRNA Nasdaq
- Market Cap
- APPN 2.8B
- VRNA 3.4B
- IPO Year
- APPN 2017
- VRNA 2017
- Fundamental
- Price
- APPN $33.89
- VRNA $46.59
- Analyst Decision
- APPN Hold
- VRNA Strong Buy
- Analyst Count
- APPN 5
- VRNA 6
- Target Price
- APPN $40.75
- VRNA $43.83
- AVG Volume (30 Days)
- APPN 359.6K
- VRNA 909.7K
- Earning Date
- APPN 02-13-2025
- VRNA 02-27-2025
- Dividend Yield
- APPN N/A
- VRNA N/A
- EPS Growth
- APPN N/A
- VRNA N/A
- EPS
- APPN N/A
- VRNA N/A
- Revenue
- APPN $595,656,000.00
- VRNA $5,624,000.00
- Revenue This Year
- APPN $14.96
- VRNA N/A
- Revenue Next Year
- APPN $11.19
- VRNA $644.06
- P/E Ratio
- APPN N/A
- VRNA N/A
- Revenue Growth
- APPN 13.28
- VRNA 1127.95
- 52 Week Low
- APPN $26.28
- VRNA $11.39
- 52 Week High
- APPN $43.33
- VRNA $48.91
- Technical
- Relative Strength Index (RSI)
- APPN 40.78
- VRNA 64.16
- Support Level
- APPN $32.21
- VRNA $45.05
- Resistance Level
- APPN $34.97
- VRNA $48.91
- Average True Range (ATR)
- APPN 1.35
- VRNA 2.39
- MACD
- APPN -0.34
- VRNA 0.35
- Stochastic Oscillator
- APPN 26.65
- VRNA 76.23
About APPN Appian Corporation
Appian is a low-code enterprise platform-as-a-service company focusing on business process management. The Appian platform is an integrated automation platform providing tools for organizations to design, automate, and optimize end-to-end processes and complex business operations. Capabilities include case management, robotic process automation, artificial intelligence, data fabric, and process mining. Most of Appian's revenue is subscription based with the remainder from services, with much of its subscription revenue being derived from its cloud-based platform, Appian Cloud.
About VRNA Verona Pharma plc
Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.